Kitching, A. Richard
Anders, Hans-Joachim
Basu, Neil
Brouwer, Elisabeth
Gordon, Jennifer
Jayne, David R.
Kullman, Joyce
Lyons, Paul A.
Merkel, Peter A.
Savage, Caroline O. S.
Specks, Ulrich
Kain, Renate
Article History
Accepted: 14 July 2020
First Online: 27 August 2020
Competing interests
: A.R.K. is Chair of the Board of the Australian and New Zealand Vasculitis Society and has been a consultant for CSL Limited and Visterra. N.B. has received research funding from Vifor and GSK and speaking fees from Roche and Vifor. E.B. received consultancy and speaker fees from Roche, which were paid to her employer. D.R.J. has been a consultant for ChemoCentryx, InflaRx and Insmed. P.A.L. holds founding equity in and receives consultation fees from PredictImmune Ltd. P.A.M. has been a consultant for AbbVie, Biogen, CSL Behring, Genzyme, Insmed, Janssen, Kiniska and Sparrow, received research funding and consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GSK and InflaRx, and grant support from Kypha. U.S. has been a consultant for AstraZeneca, Insmed, and ChemoCentryx and has received research funding from Genentech, Bristol-Myers Squibb, ChemoCentryx and GSK. The remaining authors declare no competing interests.